EP2603521A4 - Molécules d'anticorps dirigées contre des isoformes oncogènes du récepteur 2 du facteur de croissance des fibroblastes et leurs utilisations - Google Patents

Molécules d'anticorps dirigées contre des isoformes oncogènes du récepteur 2 du facteur de croissance des fibroblastes et leurs utilisations

Info

Publication number
EP2603521A4
EP2603521A4 EP11817134.7A EP11817134A EP2603521A4 EP 2603521 A4 EP2603521 A4 EP 2603521A4 EP 11817134 A EP11817134 A EP 11817134A EP 2603521 A4 EP2603521 A4 EP 2603521A4
Authority
EP
European Patent Office
Prior art keywords
growth factor
factor receptor
fibroblast growth
antibody molecules
oncogenic isoforms
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
EP11817134.7A
Other languages
German (de)
English (en)
Other versions
EP2603521A2 (fr
Inventor
Xiao-Jia Chang
Ullrich S Schwertschlag
Katherine Jane Turner
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
ATTOGEN Inc
Original Assignee
ATTOGEN Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by ATTOGEN Inc filed Critical ATTOGEN Inc
Publication of EP2603521A2 publication Critical patent/EP2603521A2/fr
Publication of EP2603521A4 publication Critical patent/EP2603521A4/fr
Withdrawn legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2863—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for growth factors, growth regulators
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/33—Crossreactivity, e.g. for species or epitope, or lack of said crossreactivity
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
    • C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
    • C07K2317/622—Single chain antibody (scFv)
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
EP11817134.7A 2010-08-12 2011-08-12 Molécules d'anticorps dirigées contre des isoformes oncogènes du récepteur 2 du facteur de croissance des fibroblastes et leurs utilisations Withdrawn EP2603521A4 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US37307210P 2010-08-12 2010-08-12
PCT/US2011/047650 WO2012021841A2 (fr) 2010-08-12 2011-08-12 Molécules d'anticorps dirigées contre des isoformes oncogènes du récepteur 2 du facteur de croissance des fibroblastes et leurs utilisations

Publications (2)

Publication Number Publication Date
EP2603521A2 EP2603521A2 (fr) 2013-06-19
EP2603521A4 true EP2603521A4 (fr) 2014-10-01

Family

ID=45568223

Family Applications (1)

Application Number Title Priority Date Filing Date
EP11817134.7A Withdrawn EP2603521A4 (fr) 2010-08-12 2011-08-12 Molécules d'anticorps dirigées contre des isoformes oncogènes du récepteur 2 du facteur de croissance des fibroblastes et leurs utilisations

Country Status (3)

Country Link
EP (1) EP2603521A4 (fr)
CN (1) CN103201287B (fr)
WO (1) WO2012021841A2 (fr)

Families Citing this family (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8663635B2 (en) 2006-03-21 2014-03-04 The Regents Of The University Of California N-cadherin: target for cancer diagnosis and therapy
WO2009124281A2 (fr) * 2008-04-04 2009-10-08 The Regents Of The University Of California Nouveaux anticorps contre la croissance tumorale dans un bloc cible, l’angiogenèse et la métastase du cancer
US9260525B2 (en) 2008-02-04 2016-02-16 Xiao-Jia Chang Antibody molecules to oncogenic isoforms of fibroblast growth factor receptor-2 and uses thereof
SG185487A1 (en) 2010-05-11 2012-12-28 Aveo Pharmaceuticals Inc Anti-fgfr2 antibodies
CN104334724B (zh) * 2012-04-09 2020-09-01 第一三共株式会社 抗-fgfr2抗体
WO2014089193A1 (fr) * 2012-12-04 2014-06-12 Aveo Pharmaceuticals, Inc. Anticorps anti-fgfr2
US9498532B2 (en) 2013-03-13 2016-11-22 Novartis Ag Antibody drug conjugates
US9415118B2 (en) * 2013-03-13 2016-08-16 Novartis Ag Antibody drug conjugates
TWI679021B (zh) 2013-08-01 2019-12-11 美商戊瑞治療有限公司 無海藻糖基化抗fgfr2iiib抗體
WO2016171107A1 (fr) * 2015-04-20 2016-10-27 第一三共株式会社 Détection de fgfr2
MX2018006181A (es) * 2015-11-23 2018-09-24 Five Prime Therapeutics Inc Inhibidores de fgfr2 solos o en combinacion con agentes que estimulan el sistema inmunitario en el tratamiento contra el cancer.
CN107513106A (zh) * 2016-06-17 2017-12-26 艾托金生物医药（苏州）有限公司 抗FGFR2-IIIc单克隆抗体、杂交瘤细胞株和应用
WO2018060688A1 (fr) * 2016-09-27 2018-04-05 The University Of The Highlands And Islands Biomarqueurs antigéniques
WO2018213304A1 (fr) 2017-05-16 2018-11-22 Five Prime Therapeutics, Inc. Anticorps anti-fgfr2 en combinaison avec des agents de chimiothérapie dans le traitement du cancer
KR102539445B1 (ko) * 2020-11-25 2023-06-05 (주)케어젠 미세먼지에 의한 세포 손상 방지 활성을 갖는 펩타이드 및 이의 용도
CN113150135B (zh) * 2021-04-14 2022-09-20 中山大学 抗新型冠状病毒受体结合区域中和抗体及其应用

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2009100105A2 (fr) * 2008-02-04 2009-08-13 Attogen Inc. Inhibiteurs d'isoformes oncogènes et leurs utilisations

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TWI353992B (en) * 2003-07-22 2011-12-11 Schering Ag Rg1 antibodies and uses thereof
WO2006121207A1 (fr) * 2005-05-12 2006-11-16 Oncotherapy Science, Inc. Procedes pour endommager des cellules en utilisant une fonction effectrice d’un anticorps anti-dsc2
CA2657953A1 (fr) * 2005-07-19 2007-01-25 University Of Rochester Anticorps d'alpha-synucleine et techniques associees
EP2020419A1 (fr) * 2007-07-31 2009-02-04 Bayer Schering Pharma Aktiengesellschaft Fragments d'anticorps anti-ephB4
PT2365828E (pt) * 2008-11-07 2014-12-12 Galaxy Biotech Llc Anticorpos monoclonais para o receptor 2 do factor de crescimento de fibroblastos

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2009100105A2 (fr) * 2008-02-04 2009-08-13 Attogen Inc. Inhibiteurs d'isoformes oncogènes et leurs utilisations

Also Published As

Publication number Publication date
WO2012021841A3 (fr) 2012-06-14
WO2012021841A2 (fr) 2012-02-16
CN103201287B (zh) 2016-04-13
EP2603521A2 (fr) 2013-06-19
CN103201287A (zh) 2013-07-10

Similar Documents

Publication Publication Date Title
EP2603521A4 (fr) Molécules d'anticorps dirigées contre des isoformes oncogènes du récepteur 2 du facteur de croissance des fibroblastes et leurs utilisations
HK1244496A1 (zh) 抗體muc16及其使用方法
HK1211607A1 (en) Chimeric fibroblast growth factor 21 proteins and methods of use 21
ZA201303803B (en) Humanized antibodies to liv-1 and use of same to treat cancer
HK1249533A1 (zh) 多聚體il-15可溶性融合分子與其製造與使用方法
EP2543060A4 (fr) Systèmes et procédés permettant d'appliquer des substances optiques à des éléments optiques
EP2632490A4 (fr) Nouvelles molécules se liant au récepteur egf et immunoconjugués de celles-ci
EP2582729A4 (fr) Anticorps anti-axl, et procédés d'utilisation.
EP2638149A4 (fr) Immortalisation de cellules épithéliales et leurs procédés d'utilisation
HK1202800A1 (en) Therapeutic uses of fibroblast growth factor 21 proteins 21
HK1209060A1 (en) Antibodies to endoplasmin and their use
IL232950A0 (en) Antibodies against the her3 receptor that bind to its domain iii and domain iv
EP2655410A4 (fr) Protéines anti-inflammatoires et procédés de préparation et d'utilisation de celles-ci
EP2558496A4 (fr) Anticorps anti-polyubiquitine et procédés d'utilisation
ZA201300174B (en) Anti-neuropilin antibodies and methods of use
HK1189501A1 (zh) 抗體組合物及使用方法
IL229748A0 (en) Compounds that bind to human β1-adrenoceptor (ß1-ar) and their use in the measurement of ar-a1 autoantibodies
EP2538935A4 (fr) Suppression du développement du cancer et des métastases en utilisant des dérivés d'acide nordihydroguaïarétique avec de la 7-hydroxystaurosporine
EP2603459A4 (fr) Synthèse de stannane et de deutérostannane
EP2624830A4 (fr) Procédés d'utilisation de modulateurs à petite molécule de l'activité du facteur de croissance (facteur de dispersion) de cellules hépatiques
HUP1100092A2 (en) Arrangement for production and using of biogas
TWM386327U (en) Girder structure made of bamboo
TWM386067U (en) Structure to make the top of van higher and to reinforce the same

Legal Events

Date Code Title Description
PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

17P Request for examination filed

Effective date: 20130307

AK Designated contracting states

Kind code of ref document: A2

Designated state(s): AL AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC MK MT NL NO PL PT RO RS SE SI SK SM TR

DAX Request for extension of the european patent (deleted)
A4 Supplementary search report drawn up and despatched

Effective date: 20140828

RIC1 Information provided on ipc code assigned before grant

Ipc: A61K 39/395 20060101ALI20140822BHEP

Ipc: C07K 16/00 20060101AFI20140822BHEP

Ipc: C07K 16/28 20060101ALI20140822BHEP

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: THE APPLICATION IS DEEMED TO BE WITHDRAWN

18D Application deemed to be withdrawn

Effective date: 20150303